HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at ...

Summary of Technova Conference Call Company Overview - **Company**: Technova - **Industry**: Life Sciences, specifically reagents for biotech, pharma, and diagnostics - **Founded**: 1996 by a scientist from Genentech - **Public Offering**: Took the company public in February 2021 Key Points and Arguments - **Market Position**: Technova is a leading provider of reagents for the life science community, serving over 3,000 customers in the U.S. [3][4] - **Growth Trajectory**: The company has historically grown at 12% since February 2009 and aims for a top-line growth of 20-25% due to clinical programs in the pipeline [4][47] - **Revenue Potential**: Technova is positioned to scale its business to $200-250 million in revenue without significant additional capital expenditures (CapEx) [4][41] - **Gross Margin**: 70% of every additional dollar in revenue contributes to the bottom line, indicating strong profitability potential [5][56] - **Customer Retention**: The company boasts a 95% retention rate of its customer base year on year, making it difficult for customers to switch suppliers [53] Product Offerings - **Product Categories**: - Catalog products (60% of business) for general R&D and academic use [16] - Custom products (35% of business), with 25% of that being biopharma-related [18] - **Growth in Custom Products**: Custom biopharma products grew by 40% last year, indicating strong demand [18] - **Speed of Delivery**: Technova can deliver research-use products in 2-3 weeks and custom GMP products in 4-8 weeks, significantly faster than competitors who may take 4-8 months [28][29] Competitive Advantage - **Customization and Quality**: Technova focuses on providing high-quality, customized reagents quickly, which is a gap in the market compared to larger players [10][19] - **Modular Manufacturing**: The company employs a modular manufacturing approach, allowing for flexibility in production sizes and formulations [25][27] - **Customer Service**: High levels of customer service and support, reflected in a net promoter score in the seventies [22] Financial Outlook - **Capital Position**: Technova had $26 million in cash at the end of Q1 and an untapped revolving line of credit, providing a solid financial foundation [61] - **Path to Profitability**: Adjusted EBITDA breakeven is expected at $50-55 million in revenue, with cash flow positive anticipated shortly thereafter [62] Industry Context - **Biotech Environment**: The company is navigating a challenging biotech funding environment but continues to gain clinical customers, projecting a 15% growth in this segment by 2025 [52] - **Regulatory Impact**: Technova feels insulated from tariff impacts due to its U.S.-based manufacturing and limited reliance on foreign raw materials [49][50] Future Strategies - **Partnerships and Collaborations**: Technova is looking to expand partnerships, such as the recent collaboration with Pluristics for cryopreservation media, to enhance its product offerings [45][58] - **Focus on Emerging Therapies**: The company aims to support the growing complexity in bioprocessing for therapies like cell and gene therapy, which require more customized solutions [36][39] Conclusion - **Long-term Growth**: Technova is positioned for sustainable growth with a strong foundational business, significant investments already made, and a clear strategy to scale operations without the need for further major investments [47][48]

PART I. FINANCIAL INFORMATION [Condensed Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Condensed%20Financial%20Statements%20(Unaudited)) Unaudited Q1 2025 financials show revenue up 5.4% to $9.8M and net loss reduced to $4.6M, with key notes - In January 2024, the company implemented a workforce reduction of approximately **35 positions**, incurring **$1.3 million** in related costs for severance and termination benefits, which were recorded in Q1 2024[32](index=32&type=chunk) - On March 3, 2025, the company entered into a Second Amended and Restated Credit Agreement with MidCap Financial Trust, providing a **$28.245 million** credit facility, including a **$23.245 million** term loan and a **$5.0 million** revolver, maturing on March 1, 2030[52](index=52&type=chunk)[53](index=53&type=chunk)[56](index=56&type=chunk) - In January 2024, the company repriced **1,631,016** outstanding stock options, resulting in an incremental stock-based compensation expense of **$0.9 million**[64](index=64&type=chunk)[65](index=65&type=chunk) - A legal claim from a former employee regarding labor laws was settled for **$0.4 million**, accrued as of March 31, 2025, and paid in April 2025[75](index=75&type=chunk) [Condensed Statements of Operations](index=5&type=section&id=Condensed%20Statements%20of%20Operations) Q1 2025 revenue rose to $9.8M, gross profit to $3.0M, and reduced operating expenses narrowed net loss to $4.6M Condensed Statements of Operations (Unaudited) | | For the Three Months Ended March 31, | | | :--- | :--- | :--- | | (in thousands, except per share data) | **2025** | **2024** | | **Revenue** | **$9,795** | **$9,290** | | Gross profit | $3,007 | $2,209 | | Loss from operations | $(4,964) | $(7,986) | | **Net loss** | **$(4,645)** | **$(8,097)** | | Net loss per share—basic and diluted | $(0.09) | $(0.20) | [Condensed Balance Sheets](index=6&type=section&id=Condensed%20Balance%20Sheets) Total assets decreased to $114.0M as of March 31, 2025, primarily due to reduced cash and investments Condensed Balance Sheet Highlights (Unaudited) | | As of March 31, 2025 | As of December 31, 2024 | | :--- | :--- | :--- | | (in thousands) | | | | Cash and cash equivalents | $3,377 | $3,708 | | Short-term investments, held-to-maturity | $22,896 | $26,688 | | Total current assets | $39,733 | $42,776 | | **Total assets** | **$113,993** | **$118,769** | | Total current liabilities | $7,045 | $11,211 | | Long-term debt, net | $12,989 | $9,443 | | **Total liabilities** | **$35,388** | **$36,375** | | **Total stockholders' equity** | **$78,605** | **$82,394** | [Condensed Statements of Cash Flows](index=8&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) Net cash used in operating activities improved to $4.1M in Q1 2025, with overall cash decreasing by $0.3M Condensed Statements of Cash Flows (Unaudited) | | For the Three Months Ended March 31, | | | :--- | :--- | :--- | | (in thousands) | **2025** | **2024** | | Net cash used in operating activities | $(4,103) | $(6,558) | | Net cash provided by investing activities | $3,824 | $13 | | Net cash used in financing activities | $(52) | $(343) | | **Change in cash and cash equivalents** | **$(331)** | **$(6,888)** | | Cash and cash equivalents at end of period | $3,377 | $21,596 | [Notes to Financial Statements](index=9&type=section&id=Notes%20to%20Financial%20Statements) Notes detail revenue disaggregation, a new credit agreement with covenants, and a significant customer concentration Revenue by Product Category (in thousands) | Product Category | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Lab Essentials | $8,117 | $7,266 | | Clinical Solutions | $1,162 | $1,718 | | Other | $516 | $306 | | **Total revenue** | **$9,795** | **$9,290** | - A single distributor customer accounted for **22%** of revenue in Q1 2025, up from **16%** in Q1 2024[40](index=40&type=chunk) - The new credit agreement includes a minimum net revenue requirement of **$39.0 million** for the twelve months ending December 31, 2025, and a minimum cash requirement of **$8.0 million**[55](index=55&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=20&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management analyzes Q1 2025 results, highlighting a 5.4% revenue increase, improved gross margin, and reduced operating expenses [Results of Operations](index=22&type=section&id=Results%20of%20Operations) Q1 2025 revenue increased by 5.4% to $9.8M, driven by Lab Essentials growth, improving gross margin and narrowing net loss Results of Operations Comparison (in thousands) | | Q1 2025 | Q1 2024 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | **Revenue** | **$9,795** | **$9,290** | **$505** | **5.4%** | | Gross profit | $3,007 | $2,209 | $798 | 36.1% | | Total operating expenses | $7,971 | $10,195 | $(2,224) | (21.8)% | | Loss from operations | $(4,964) | $(7,986) | $3,022 | (37.8)% | | **Net loss** | **$(4,645)** | **$(8,097)** | **$3,452** | **(42.6)%** | - The increase in total revenue was driven by a **$0.9 million (11.7%)** rise in Lab Essentials revenue, attributed to an increased number of customers[88](index=88&type=chunk) - Clinical Solutions revenue decreased by **$0.6 million (32.4%)** due to lower average revenue per customer[89](index=89&type=chunk) - The gross profit margin increased to **30.7%** in Q1 2025 from **23.8%** in Q1 2024, primarily due to higher revenue and lower overhead costs[92](index=92&type=chunk) [Liquidity and Capital Resources](index=25&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2025, the company had $32.7M in net working capital, supported by cash and a new credit facility - As of March 31, 2025, the company had **$32.7 million** in net working capital, which included **$26.3 million** in cash and cash equivalents and short-term investments[100](index=100&type=chunk) - The company entered into a Second Amended and Restated Credit Agreement on March 3, 2025, providing for up to **$28.245 million** in loan commitments, subject to covenants including minimum revenue and cash requirements[101](index=101&type=chunk) Net Cash Flow Summary (in thousands) | | For the Three Months Ended March 31, | | | :--- | :--- | :--- | | | **2025** | **2024** | | Net cash used in operating activities | $(4,103) | $(6,558) | | Net cash provided by investing activities | $3,824 | $13 | | Net cash used in financing activities | $(52) | $(343) | [Quantitative and Qualitative Disclosures About Market Risk](index=27&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company, as a smaller reporting entity, is not required to provide market risk disclosures - Alpha Teknova is a smaller reporting company and is not required to provide quantitative and qualitative disclosures about market risk[113](index=113&type=chunk) [Controls and Procedures](index=27&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded the company's disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal controls - Management, including the Chief Executive Officer and Chief Financial Officer, concluded that the company's disclosure controls and procedures were effective as of March 31, 2025[116](index=116&type=chunk) - There were no changes in internal control over financial reporting during the quarter ended March 31, 2025, that have materially affected, or are reasonably likely to materially affect, internal controls[117](index=117&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=30&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings, with other contingencies detailed in the financial notes - The company is not a party to any material legal proceedings at this time[121](index=121&type=chunk) [Risk Factors](index=31&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors from the 2024 Annual Report, reiterating ongoing operating losses and potential stock dilution - The company has a history of operating losses, including a net loss of **$4.6 million** for the three months ended March 31, 2025, and may incur losses in the future[124](index=124&type=chunk) - A significant portion of the company's **53,437,060** outstanding shares of common stock are available for resale, which could cause the market price to drop[125](index=125&type=chunk)[126](index=126&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=32&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities or stock repurchases during the quarter - There were no unregistered sales of equity securities or company stock repurchases during the reported quarter[129](index=129&type=chunk)[131](index=131&type=chunk) [Defaults Upon Senior Securities](index=32&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - None[132](index=132&type=chunk) [Mine Safety Disclosures](index=32&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[133](index=133&type=chunk) [Other Information](index=32&type=section&id=Item%205.%20Other%20Information) A board member adopted a Rule 10b5-1 trading plan to sell shares for tax obligations, with no other similar plans by officers or directors - On March 12, 2025, board member Martha J. Demski adopted a Rule 10b5-1 trading plan to sell a maximum of **8,000 shares** of common stock, with sales eligible to begin on June 27, 2025[134](index=134&type=chunk) - No other officers or directors adopted, modified, or terminated a Rule 10b5-1 trading arrangement during the first quarter of 2025[135](index=135&type=chunk) [Exhibits](index=32&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including credit agreements and SOX certifications - The filing includes key exhibits such as the Second Amended and Restated Credit Agreements (Term Loan and Revolving Loan) and certifications from the CEO and CFO pursuant to Sarbanes-Oxley Act Sections 302 and 906[136](index=136&type=chunk)[137](index=137&type=chunk)

Alpha Teknova (TKNO) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Jennifer Henry - Senior Vice President of MarketingStephen Gunstream - President & CEOMatthew Lowell - Chief Financial OfficerVidyun Bais - Equity Research - Vice PresidentChad Wiatrowski - VP - Equity Research Conference Call Participants Anna Snopkowski - Equity Research AnalystMatthew Hewitt - Senior Research AnalystMatt Larew - Research Analyst - Healthcare Operator Good day, and thank you for standing by. Welcome t ...

Alpha Teknova (TKNO) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Tecnova First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw y ...

FINANCIAL RESULTS: Q1:2025 SLIDE SUPPLEMENT Nasdaq: TKNO May 8, 2025 • Welcome • Business Highlights and Updates Stephen Gunstream, President and Chief Executive Officer • Financial Results and 2025 Outlook Matt Lowell, Chief Financial Officer • Q&A Forward-looking statements and use of non-GAAP financial measures Today's Agenda © 2025 Alpha Teknova, Inc. ● Financial Results | Q1:2025 ● Slide Supplement May 8, 2025 2 Statements in this presentation about future expectations, plans, and prospects, as well as ...

Exhibit 99.1 Teknova Reports First Quarter 2025 Financial Results First quarter 2025 total revenue was $9.8 million, up 5% from prior year Company introduced proprietary PluriFreezeTM cryopreservation system, in collaboration with Pluristyx, Inc. Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 8, 2025 – Alpha Teknova, Inc. ("Teknova" or the "Company") (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therap ...

Core Insights - Alpha Teknova, Inc. reported total revenue of $9.8 million for the first quarter of 2025, reflecting a 5% increase from $9.3 million in the same period of 2024 [1][5] - The company introduced the proprietary PluriFreeze™ cryopreservation system in collaboration with Pluristyx, Inc., enhancing its cell therapy product portfolio [1][8] - Teknova reaffirmed its revenue guidance for 2025, expecting total revenue between $39 million and $42 million [1][11] Financial Performance - Lab Essentials revenue reached $8.1 million, a 12% increase from $7.3 million in Q1 2024, while Clinical Solutions revenue decreased by 32% to $1.2 million from $1.7 million [4][5] - Gross profit for Q1 2025 was $3.0 million, with a gross margin of 30.7%, up from 23.8% in Q1 2024, driven by higher revenue and lower overhead costs [6] - Operating expenses decreased to $8.0 million from $10.2 million in Q1 2024, primarily due to lower stock-based compensation and reduced spending [7] Cash Flow and Losses - The net loss for Q1 2025 was $4.6 million, or negative $0.09 per diluted share, compared to a net loss of $8.1 million, or negative $0.20 per diluted share, in Q1 2024 [9][21] - Adjusted EBITDA improved to negative $2.5 million from negative $3.8 million year-over-year, while free cash flow was negative $4.3 million, an improvement from negative $6.7 million in Q1 2024 [10][27] Strategic Developments - The collaboration with Pluristyx, Inc. positions Teknova as the exclusive manufacturer and distributor of the PluriFreeze™ product line in the U.S. and Canada, expanding its market reach [1][8] - The company maintains a strong cash position with total cash and short-term investments of $26.3 million and total borrowings of $13.2 million at the end of Q1 2025 [8]

Core Viewpoint - Alpha Teknova, Inc. is set to report its financial results for Q1 2025 on May 8, 2025, after market close, indicating a focus on transparency and communication with investors [1]. Group 1: Financial Reporting - The company will announce its financial results for the first quarter ended March 31, 2025, on May 8, 2025 [1]. - A webcast and conference call will be held on the same day at 5 p.m. Eastern Time for investors to access the results [2]. Group 2: Company Overview - Teknova has been innovating in the manufacture of critical reagents since 1996, supporting the life sciences industry [3]. - The company offers customizable solutions for various stages of the workflow, aiding in molecular diagnostics, synthetic biology, and emerging therapeutic modalities [3]. - Teknova operates from a 180,000 square feet facility in Hollister, California, designed for efficient production of foundational ingredients for next-generation therapies [3].

HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, while Pluristyx is a leading provider of induced Pluripotent Stem Cells (iPSCs), including immune evading ...